GLP-1s and pregnancy: what each label says, and when it says to stop
Every weight-loss label on this site addresses pregnancy, and they do not agree on the one thing someone planning a pregnancy needs: how far ahead to stop. Only the three semaglutide labels give a number.
Can you take a GLP-1 while pregnant, and when should you stop?
No label here supports taking a weight-loss drug through pregnancy. The labels written for weight loss — Wegovy, Zepbound, Saxenda, Foundayo and Contrave — say weight loss offers no benefit to a pregnant patient and may cause fetal harm, and to stop when a pregnancy is recognized. Qsymia and phentermine go further: both are contraindicated in pregnancy, and Qsymia requires a negative pregnancy test before the first dose and every month after.
On planning ahead they split. Wegovy, Ozempic and the semaglutide tablets say to stop at least 2 months before a planned pregnancy, because semaglutide takes that long to wash out. The tirzepatide labels, Zepbound and Mounjaro, name no interval, and neither does Foundayo. Tirzepatide carries a second warning that bears on pregnancy: it can make the contraceptive pill less reliable after each dose increase.
Last updated 2026-09-02 — the newest FDA label version quoted below. Read and dated by Alex Seot.
Label by label
Quoted from section 8 of each FDA label, with the date of the version read. The first line of each is the short answer; the quotation is the label's own.
Stop at least 2 months before a planned pregnancy
“Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide.”
Stop at least 2 months before a planned pregnancy
“Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.”
Stop at least 2 months before a planned pregnancy
“Discontinue RYBELSUS or OZEMPIC tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.”
Stop when a pregnancy is recognized; no interval for planning
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized.”
Only if the benefit justifies the risk; no interval for planning
“MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
Stop when a pregnancy is recognized; use effective contraception
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue FOUNDAYO.”
Stop when a pregnancy is recognized
“When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus, and discontinue SAXENDA.”
Stop when a pregnancy is recognized
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to the fetus, and discontinue CONTRAVE.”
Contraindicated; a pregnancy test before starting and every month
“QSYMIA is contraindicated in pregnant patients. … Pregnancy testing is recommended in patients who can become pregnant before initiating QSYMIA and monthly during QSYMIA therapy.”
Contraindicated
“Phentermine is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm.”
Only if the benefit justifies the risk
“TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
Only if the benefit justifies the risk
“VICTOZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
Outside the labels
Among 938 infants of mothers with type 2 diabetes who filled a GLP-1 prescription around conception or in the first trimester, major malformations were no more common than with insulin (adjusted relative risk 0.95, 95% CI 0.72 to 1.26), across cohorts from four Nordic countries, the US and Israel. A diabetes population at diabetes doses, not weight-loss doses.
GLP-1s and pregnancy, answered
- How long before trying to conceive should I stop Wegovy or Ozempic?
- At least 2 months, according to the Wegovy, Ozempic and semaglutide-tablet labels, because semaglutide has a long half-life and takes that long to clear. The Zepbound and Mounjaro labels give no interval; they say to stop when a pregnancy is recognized. The prescriber also has to weigh what stopping does to weight and, for Ozempic, to blood sugar.
- What if I got pregnant while taking a GLP-1?
- The weight-loss labels say to stop when the pregnancy is recognized and to be told the risk to the fetus. Wegovy, Zepbound and Foundayo each run a pregnancy exposure registry for exactly this situation, and their labels print how to reach it. The largest observational study so far, in women with type 2 diabetes, found malformations no more common than with insulin.
- Why are Qsymia and phentermine contraindicated when the GLP-1s are not?
- Because the evidence of harm differs. Qsymia contains topiramate, which its label ties to fetal harm, so it requires a pregnancy test before starting and every month, and effective contraception throughout. Phentermine's label is Pregnancy Category X. The GLP-1 labels rest on animal findings and too little human data to settle the question, which produces 'discontinue' rather than 'contraindicated'.
- Does Wegovy's advice change if I take it for my heart?
- Its label says to discontinue Wegovy in pregnant patients who are using it for weight reduction — worded that way because Wegovy also carries a cardiovascular indication. The 2-month planning interval in section 8.3 is not limited to weight use.